Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Lantmännen in connection with its acquisition of the remaining shares in Scandbio
Mandate

Vinge advises Lantmännen in connection with its acquisition of the remaining shares in Scandbio

February 21, 2022 EU, Competition and Regulatory M&A

Vinge has advised Lantmännen in connection with its acquisition of the remaining shares in Scandbio AB. Scandbio AB was founded in 2014 when Lantmännen merged its operations with the Finnish company Neova. Both owners have held an equal number of shares in the 50/50 joint venture company since 2014.

Scandbio is Sweden’s largest company in the fixed refined forestry fuel sector with an annual turnover of around MSEK 1 000. The company is headquartered in Jönköping with operations at five sites in Sweden and one in Latvia. Scandbio manufactures, markets and sells wood pellets fuel to Sweden, Denmark and the Baltic States as well as stable pellets for the Swedish market. The company provides both industrial facilities as well as municipal and state-owned operations, local entrepreneurs and individual home owners with 100 per cent renewable energy.

The transaction is subject to the requisite approvals by the competition authorities.

Vinge’s team consisted of Christina Kokko and Elsie Nassar (M&A) together with Marcus Glader, Johan Wahlbom and Jesper Ekman (Merger filing).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025